Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model.
A recently published post-hoc analysis of a trial using high-dose antithrombin (AT) in septic patients (KyberSept) revealed significant reduction of lethality when no concomitant heparin was administered, whereas patients with the combination of heparin and AT did not benefit in terms of survival. Therefore, it seems feasible to study the capability of AT in prevention of microvascular thrombus formation to avoid concomitant application of heparin and AT. Using fluorescence microscopy and a light/dye-injury mouse ear model, the kinetics of thrombus formation were analyzed quantitatively in vivo upon single iv bolus of saline (control), heparin (100 IU/kg), hirudin (1 mg/kg) or AT (25, 50, 100 or 250 IU/kg) (N = 7 animals per group each). In controls, light/dye-injury induced complete thrombotic occlusion in all arterioles and venules studied. Heparin and hirudin prevented thrombotic vessel occlusion in 62% and 43% of arterioles and 11% and 28% of venules. AT-250 was found to be more effective than heparin and hirudin, because thrombus formation was completely banned in all arterioles and venules. AT-100 and AT-50 were also capable of significantly blocking thrombus formation in both arterioles and venules. In blood vessels, which finally clogged, the time for development of complete vessel occlusion was delayed after heparin, hirudin and AT-25, but in particular after AT-50 and AT-100. In conclusion, AT-mediated antithrombotic activity has been characterized in a model of phototoxicity-induced microvascular thrombosis formation, demonstrating that AT delays and prevents thrombus formation in arterioles and venules at least comparably effective as heparin and hirudin.
Sorg
Heiko
H
Department of Experimental Surgery, University of Rostock, Rostock, Germany.
Hoffmann
Johannes N
JN
Menger
Michael D
MD
Lindenblatt
Nicole
N
Goehring
Peter
P
Vollmar
Brigitte
B
D000818:Animals; D000991:Antithrombins / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006493:Heparin / Q000494:pharmacology*; D006629:Hirudins / Q000494:pharmacology*; D006720:Homozygote; D007700:Kinetics; D008297:Male; D051379:Mice; D008833:Microcirculation / Q000378:metabolism*; D008856:Microscopy, Fluorescence; D013927:Thrombosis / Q000473:pathology* / Q000517:prevention & control*; D016896:Treatment Outcome
D000991:Antithrombins; D005343:Fibrinolytic Agents; D006629:Hirudins; D006493:Heparin